Abstract
e17018 Background: Recent studies have shown promising risk modifying effects of statin in various hematologic and solid tumors, such as its ability to induce apoptosis in acute myeloid leukemia cells in-vitro. The impact of statin on MDS treatment outcome has not been evaluated. In this retrospective study, we have examined the overall survival (OS) in veteran MDS patients (pts) with and without exposure to statin with the initial hypothesis that it may impact OS. Methods: After IRB approval, data was collected from Michael E DeBakey VAMC Cancer Registry from January 2000 to October 2011. Pts were included if they had morphological evidence of MDS at the time of diagnosis. Statin exposure was defined as concurrent statin use for at least 6 months prior to and at the time of diagnosis. The primary end-point was OS before and after adjustment with MDS Co-morbidity Index (MDS-CI). Prism 5 was used for statistical analysis. Results: 104 pts with MDS were identified with baseline characteristics depicted in the table. OS of pts exposed to statin was significantly longer when compared with pts not exposed to statin (950d vs 419d, p<0.05). This improvement was especially prominent in pts with higher comorbidities (MDS-CI score>2) (1062d vs 219d, p<0.05) and specifically in those with higher cardiac comorbidities. OS in pts with lower MDS-CI scores was higher in patients on statin but there was no statistical significance (901d vs 663d, p=0.57). Conclusions: In this retrospective study, concurrent statin exposure significantly improved OS in pts with MDS. This improvement, however, was statistically significant in pts with higher overall and cardiovascular co-morbidities. These findings suggest a limited direct anti-tumor benefit of statin in MDS, although the results may have been influenced by the sample size and retrospective design. Prospective studies after stratification by IPSS and MDS-CI are needed to further evaluate the risk-modifying effects of statin in MDS. [Table: see text]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
